|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.670 USD | +11.33% |
|
-.--% | +221.15% |
| 06-01 | Revium Rx. Announces CFO Changes, Effective May 27, 2026 | CI |
| 05-14 | Revium Rx. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Sales by Activity: Revium Rx.
| Fiscal Period: December | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Geographical breakdown of sales: Revium Rx.
| Fiscal Period: December | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Executive Committee: Revium Rx.
| Manager | Title | Age | Since |
|---|---|---|---|
Amir Avraham
CEO | Chief Executive Officer | - | 21/05/2025 |
Igor Bluvstein
DFI | Director of Finance/CFO | 46 | 26/05/2026 |
Inna Martin
CEO | Chief Executive Officer | 51 | - |
Ohad Rosenzweig
CTO | Chief Tech/Sci/R&D Officer | - | - |
Erez Koren
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2022 |
Composition of the Board of Directors: Revium Rx.
| Director | Title | Age | Since |
|---|---|---|---|
Inna Martin
BRD | Director/Board Member | 51 | - |
Matti Munk
BRD | Director/Board Member | - | - |
Yoram Druker
BRD | Director/Board Member | - | - |
| Chairman | - | 13/04/2026 |
Company details: Revium Rx.
Sector
This company's sector is not yet available
- Stock Market
- Stocks
- RVRC Stock
- Company Revium Rx.
Select your edition
All financial news and data tailored to specific country editions
